Skip to main content
Premium Trial:

Request an Annual Quote

Tokyo Pharma Licenses Rosetta's Biomarker Software

NEW YORK (GenomeWeb News) - Japanese pharmaceutical company Eisai has licensed Rosetta Biosoftware's Elucidator protein expression and biomarker discovery system, Rosetta said yesterday.
Seattle-based Rosetta said Eisai plans to use the Elucidator system to support LC/MS methods for biomarker research in neurology at the Laboratory of Seeds Finding Technology
Elucidator enables data management and analysis workflow for comparative proteomics, Rosetta said.
Financial terms of the deal were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.